United States: FDA's Evolving Regulation Of Artificial Intelligence In Digital Health Products

In Short

The Situation: FDA has been grappling with regulation of rapidly advancing digital products, including artificial intelligence. While Congress and FDA have provided recent clarifications, regulatory questions remain.

The Result: Both the 21st Century Cures Act and recent FDA activities provide important, but incomplete, insight regarding regulation of health products utilizing artificial intelligence.

Looking Ahead: Digital health product manufacturers should recognize how recent regulatory changes may affect them, and that FDA is engaging industry to further refine its oversight approach.

Artificial intelligence ("AI") can be broadly defined as a device or product that can imitate intelligent behavior. In the health care space, this could include a machine learning algorithm that evolves and improves as new data inputs are entered. This type of adaptive algorithm can provide physicians with diagnostic information for numerous medical conditions.

While AI-based medical products hold tremendous potential, the question of their regulation has challenged the U.S. Food and Drug Administration ("FDA"). At issue are the medical device provisions of the Federal Food, Drug, and Cosmetic Act ("FDCA"), which were initially crafted to address medical devices existing in the mid-1970s when the Medical Device Amendments were enacted. These types of products were mostly hardware based, and iterative technology design changes were relatively infrequent.

The current device landscape looks quite different. While traditional device hardware still plays a prominent role in our health care, advances in computational power and new digital platforms are redefining the way modern care is accessed and administered. From mobile medical applications and "software as a medical device" to advanced analytics and artificial intelligence, digital products now make up a sizeable portion of the device economy. These products have brought new market participants, who have in turn brought innovation and new manufacturing processes that don't fit neatly into existing regulatory boxes.

Recent Regulatory Activity

Recently, both FDA and Congress have taken steps to address industry concerns about regulation of the digital sector. FDA created a Digital Health Program tasked with developing and implementing a new regulatory model for digital health technology. Over the last five years, the program has issued several enforcement discretion guidance documents (e.g., the Mobile Medical Applications Guidance) explaining FDA's oversight approach.

While these guidance documents are certainly helpful, FDA guidance is not law, and the products addressed by these documents only scratch the surface of digital health. Because of continuing regulatory uncertainty, industry persistently has asked for more precise, binding guidance. Industry received a modicum of satisfaction when Congress enacted the 21st Century Cures Act ("Cures Act") in December 2016, which contains provisions clarifying FDA's jurisdiction over digital health products. Specifically, Section 3060 of the Cures Act excludes certain types of "medical software" from the "device" definition. While most excluded categories are relatively noncontroversial (and already within enforcement discretion policies), one category is of particular importance: software intended for:

(E)(i) displaying, analyzing, or printing medical information about a patient or other medical information (such as peer-reviewed clinical studies and clinical practice guidelines);

(ii) supporting or providing recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or condition; and

(iii) enabling such health care professional to independently review the basis for such recommendations that such software presents so that it is not the intent that such health care professional rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient.

unless the function is intended to acquire, process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system.

This type of software is generally referred to as "clinical decision support" ("CDS") software. "CDS software" is loosely defined as an application that analyzes data to help health care providers make clinical decisions. Artificial intelligence, such as machine learning algorithms, may fall into this category when used for a health purpose. Per the Cures Act, whether CDS software is excluded from FDA's jurisdiction depends on, among other things, the ability of the health care professional using the software to independently review the basis for a clinical recommendation.

To clarify this provision, FDA issued a draft guidance on December 8, 2017. The guidance discusses each prong of the exclusion and provides some interpretive clarity regarding how software might allow independent review by a health care professional. FDA says this prong will be met if the software clearly explains:

  1. The purpose or intended use of the software function;
  2. The intended user (e.g., ultrasound technicians, vascular surgeons);
  3. The inputs used to generate the recommendation (e.g., patient age and gender); and
  4. The rationale or support for the recommendation.

The guidance says that, in order to be excluded from the device definition, the user should be able to reach the same recommendation without relying primarily on the software. Further, the sources supporting the recommendation should be identified, easily accessible to and understandable by the intended user, and publicly available. However, in the context of AI-based software, it's difficult to predict how FDA might interpret this requirement, especially where the recommendation is being produced by a machine learning algorithm that may be proprietary. Considering the above, it seems likely that AI health products will exist on both sides of this newly drawn regulatory line, and uncertainty remains regarding how FDA intends to regulate products remaining under its purview.

Looking Forward

In the recently released Digital Health Innovation Action Plan, FDA acknowledges its traditional approach to hardware-based medical devices is not well suited for the faster iterative design, development, and validation used for software-based medical technologies. The report notes that the traditional premarket requirements for devices may impede or delay patient access to critical software technology, particularly those presenting a lower risk to patients. Finally, it states that "an efficient, risk-based approach to regulating digital health technology will foster innovation of digital health products." But what does that mean, and how flexible can FDA be within the existing statutory scheme?

FDA's Digital Health Software Precertification ("Pre-Cert") Pilot Program offers insight into a possible regulatory approach. According to FDA, the voluntary program is intended to help the Agency design a tailored approach to regulating software by looking at the developer of the product rather than primarily at the product, which is how FDA evaluates all other medical devices. As such, if adopted by FDA, this developer-targeted review would be a significant departure from FDA's historic approach. While promising, the Agency has yet to explain how this approach would comport with the existing statutory provisions governing devices, making one wonder whether a legislative fix may be needed prior to implementation.

The program is already underway, and pilot participants, including Apple, Fitbit, and Verily, have been selected. The participants will provide FDA access to measures they use to develop, test, and maintain software products, including ways they collect post-market data. To help build its software expertise, FDA is also conducting on-site visits. The program's stated goals are:

  • Enabling a modern and tailored approach that allows software iterations and changes to occur in a timely fashion;
  • Ensuring high-quality medical software throughout the product's life by enabling companies to demonstrate their embedded culture of quality and organization excellence; and
  • Being a program that learns and adapts and can adjust key elements and measure based on the program's effectiveness.

In addition to the Pre-Cert Program, FDA is also bolstering its software expertise through a Digital Health-Entrepreneur-in-Residence Program and has elsewhere stated it is seeking people knowledgeable in software design and business processes to work with the Agency on digital health. Finally, FDA maintains an open docket, regularly soliciting stakeholder feedback.

The upshot: The recent FDA activity demonstrates the regulatory landscape for digital health products is evolving. Presently, the Agency seems open to stakeholder input regarding software regulation. To the extent that regulated parties may have insight, thoughts, or advice to impart to FDA, now is a perfect time to do so. The Agency has been engaged and listening to stakeholders, and it has shown through its recent guidance documents a willingness to be flexible. This period of transition provides a great opportunity to engage FDA to help shape the future of digital health.

Three Key Takeaways

  1. The Cures Act recently amended the FDCA to exclude certain types of medical software from the definition of "device."
  2. Artificial intelligence-based health products may fall within an excluded category if, among other things, the software enables the health care practitioner to independently review any clinical recommendations it provides.
  3. For software remaining under FDA's purview, the Agency is activity working with industry and other stakeholders to develop a new, more efficient regulatory paradigm.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Colleen Heisey
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions